



Minutes

Date Wednesday, 06/01/2021

Time 09.00am

To Committee Members

At Virtual via Microsoft Teams

Subject AWERB 3Rs Committee

In Attendance:

Apologies:

1. Minutes

The previous minutes were approved

2. Matters Arising

3. Retrospective Reviews

The committee discussed the following:

[REDACTED] - Investigating ubiquitin ligases in disease

- Section 2.2: The committee would like the table to be completed for each protocol. This would provide some explanations regarding lower or higher observed severity.
- Section 2.3: Due to the problems with the null allele the committee wondered if this was due to the Cre in the germline? If this is the case was there another Cre that could be used to prevent this happening in the future?
- Section 2.3 – The committee would like to know if the pups that were born runty were able to be killed rather than be born and die?
- Section 2.7 Second line: simultaneous is spelt incorrectly
- Section 4.8: The committee would like to check if any of the meetings 3Rs achievements were disseminated?

[REDACTED] - Experimental molecular medicines for restorative neuroimmunology

- In section 1, the project purpose ought to match the aims of the licence, as written in section 3.5.
- In section 1, a mark should be made next to the appropriate plan for the licence
- In section 2.1, all the protocols in the licence must be included, even if they have not been used. The committee noted that the severity for each recorded protocol are the same. Is this



accurate? This should be the Actual Severity for each protocol and reflect the Home Office Annual Return of Procedures. The committee would like to draw your attention that the number limit on Protocol 9 has been almost reached.

- Section 2.1, Protocol 9 does not have the species listed here and SCI has been added instead. Please update this section.
- In section 2.3, could more information be given as to why an animal was given two anaesthetics on the same day as referenced in SC18: ASRU_CBS Cambride_PPL [REDACTED] 20 06 2019_sc18
- In section 3.5, what do the numbers in brackets refer to? Please remove if not needed.
- Section 3.6, It was noted by the committees that ulceration should not be a consequence of administration of CFA and suggest the group research this further to refine the methods that are used.
- In section 5.5, could an answer be given even if the answer is no issues?
- The committee considered if more quantitative methods could be used in the assessment of the animals by using methods such as the Digigait?
- The committees recognise the huge impact the work has achieved with the clinical trials in man and recommend this is promoted and made more transparent in this review. The committees wish to congratulate you on the work you have achieved.

[REDACTED] - In vivo assessment of novel injectable hydrogel biomaterials for spinal disc repair. **Please note this licence had not been used.**

4. Retrospective Assessments

(a) None

5. Project Licence Applications

(a) None

6. Severe Severity licence reviews

7. Standard Condition 18 reports

8. 3Rs information/reports

9. Feedback from previous Retrospective Reviews*

None

10. Minutes of AOC meeting*

None

11. Minutes of AWERB Standing meeting*

None



12. Any Other Business

- The committee discussed AWERB 3Rs TOR and the purpose of the meeting.
- The question was asked about how we share examples of how reports like RR forms should look when completed
- The role and purpose of the secretariat was discussed and it was agreed it should be an NVS
- The best way of sharing of information and increasing awareness was discussed
- The committee discussed making better use of the UBS website for access to and information sharing
- The committee discussed having a record of best practice
- The committee discussed how to better communicate that the 3Rs committee exists. It needs to be discussed with researchers how they would prefer to be communicated with.
- It was agreed to send an email to committee members to ask if they would still like to be part of the 3Rs committee.

Date of next meeting: Wednesday 3rd February 2021

***Items for information only unless un-starred by committee member**